Inhibitor development, safety and efficacy of Advate® among previously treated patients with hemophilia A in a postmarketing surveillance in Japan
- 2 January 2019
- journal article
- research article
- Published by Springer Nature in International Journal of Hematology
- Vol. 109 (3) , 336-345
Abstract
Rurioctocog alfa (recombinant factor VIII: Advate®) is available for the control of bleeding in patients with hemophilia A in Japan. To evaluate the inhibitor development, safety, and efficacy of rurioctocog alfa, a non-interventional and observational postmarketing surveillance was conducted on 352 previously treated Japanese patients aged 1–76 years with ≥ 4 exposure days under the conditions of routine clinical practice. A post-hoc comparison of the mean annualized bleeding rates which required treatment with rurioctocog alfa detected a statistically significant difference (P < 0.0001) between patients treated on regular prophylaxis (8.5 bleeds/year) and patients treated on an on-demand basis (36.6 bleeds/year). Favorable prophylactic and on-demand hemostatic efficacy (“excellent” or “good”) were shown in 88.5–100% of patients across all treatment regimens. A total of 22 events of adverse drug reactions were reported in 13 male patients. Of the 352 patients, 3 (0.9%) patients, all of whom had ≤ 50 exposure days before enrollment, developed de novo FVIII inhibitor. No deaths or allergic reactions were reported. Rurioctocog alfa was found to be well-tolerated and effective among patients with hemophilia A in a postmarketing routine clinical practice.Keywords
This publication has 20 references indexed in Scilit:
- Inhibitor development in previously treated hemophilia A patients: a systematic review, meta‐analysis, and meta‐regressionJournal of Thrombosis and Haemostasis, 2013
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Octocog Alfa, Antihaemophilic Factor (Recombinant), Plasma/Albumin Free Method (Advate®)Drugs, 2012
- Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practiceBritish Journal of Clinical Pharmacology, 2010
- Postauthorization safety surveillance of ADVATE [antihaemophilic factor (recombinant), plasma/albumin‐free method] demonstrates efficacy, safety and low‐risk for immunogenicity in routine clinical practiceHaemophilia, 2010
- Analysis of low frequency bleeding data: the association of joint bleeds according to baseline FVIII activity levelsHaemophilia, 2010
- Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe HemophiliaNew England Journal of Medicine, 2007
- Epidemiology of inhibitor formation with recombinant factor VIII replacement therapyHaemophilia, 2006
- A multi-center post-marketing surveillance study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia AJapanese Journal of Thrombosis and Hemostasis, 2005
- Elbow joint, crutches and locomotion: special reference to persons with haemophiliaHaemophilia, 2000